$AEMD

AETHLON MEDICAL INC (AEMD) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers. As described in Item 5.07 below, on October 1, 2026, at the Annual Meeting of Stockholders (the “Annual Meeting”) of Aethlon

Lisata Therapeutics acquired Marea Therapeutics in a stock-for-stock deal with a $225M private placement, gaining access to Marea's cardioendocrine pipeline. Aethlon Medical merged with North Immunology in an all-stock deal with a $180M private placement, focusing on NOR-101 for atopic dermatitis. Both deals aim to advance pipelines and create value for shareholders.

Ultragenyx (RARE) gained FDA approval for FAYUVI, a treatment for Sanfilippo syndrome Type A, closing at $14.50, up 12.58%. Nuvation Bio (NUVB) expanded IBTROZI's label with new lung cancer data, closing at $6.07, up 5.02%. Bayer (BAYRY) won FDA approval for Kerendia in type 1 diabetes-related CKD, closing at $14.13, up 0.57%. Biogen (BIIB) and Eisai (ESALY.PK) received Japan approval for LEQEMBI Pen, closing at $219.05, up 1.41%. Telix (TLX) got FDA approval for Pixclara, a PET imaging agent fo

Major U.S. indices rose on Thursday. Aethlon Medical (AEMD) surged 374.13% after a merger announcement, Oklo (OKLO) gained 11.31% on nuclear power legislation, CID HoldCo (DAIC) jumped 163.68% with an acquisition, Xenon Pharmaceuticals (XENE) increased 1.04% on FDA submission, and Moderna (MRNA) climbed 8.55% following positive cancer vaccine data.

Aethlon Medical (AEMD) surged 360% after announcing a merger with North Immunology and a $180M private placement. Tiziana Life Sciences (TLSA) rose 22% due to a clinical trial collaboration. Capricor Therapeutics (CAPR) gained 9% with upcoming Duchenne data. Firefly Neuroscience (AIFF) climbed 26% after a brain-medicine partnership. Clearmind Medicine (CMND) increased 6% following an FDA psychedelic hearing.

U.S. stocks rose midday, with S&P 500 up 1%. Pending home sales increased 0.3% in August. Aethlon Medical (AEMD) surged 390% on merger news. Datasea (DTSS) rose 81% on AI service agreements. Fluence Energy (FLNC) fell 14% after price target cuts. Oil dropped 1.4%, gold up 0.4%. European and Asian markets mixed.

Aethlon Medical (AEMD) surged over 400% after announcing a merger with North Immunology. BioAffinity Technologies (VEEA) also rose following a Hong Kong patent grant for its CyPath Lung diagnostic. Other biotech stocks saw mixed pre-market activity.

Aethlon Medical (AEMD) surged 346% premarket after announcing an all-stock merger with North Immunology, expected to close in Q1 2027. AEMD's P/S ratio is near zero, reflecting market skepticism. The combined entity, North Immunology Inc. (NRTX), is valued at $346.5M. AEMD's GF Score is 19/100, indicating weak financial health.

AETHLON MEDICAL INC (AEMD) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Aethlon Medical & North Immunology Announce Merger to Advance Novel IL-13 x IL-18 Bispecific Antibody for Atopic Dermatitis North Immunology’s lead program, NOR-101, is a half-life extended anti-IL-13 x IL-18 bispecific antibody designed to inhibit both type 2 and no

Aethlon Medical (NASDAQ:AEMD) shares surged over 400% in premarket trading after announcing a merger with North Immunology. The all-stock deal includes $180M in financing from investors. The combined entity will trade as NRTX on Nasdaq. North Immunology develops bispecific antibodies for immune diseases, with NOR-101 in development for atopic dermatitis.